Award
NIH Reporter #5U44AI152995-04
A Randomized Phase I Clinical Trial of HydroVax-CHIKV, a Novel Inactivated Chikungunya Virus Vaccine
Recipient
NAJIT TECHNOLOGIES, INC.
Award Amount
$980,257.00
Ceiling
$980,257.00
Awarded
June 12, 2026
Identifier
5U44AI152995-04
Award for a Phase I clinical trial of HydroVax-CHIKV vaccine to assess safety and immunogenicity, funded by NIAID.
Description
This project involves a Phase I clinical trial to evaluate the safety and immunogenicity of HydroVax-CHIKV, a peroxide-inactivated chikungunya virus vaccine.